Compare Stocks → The system that called 2023’s top 7 stocks is at it again… (From WealthPress) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison OTCMKTS:ASNBOTCMKTS:CTTCOTCMKTS:NVTRQOTCMKTS:RGINOTCMKTS:TEAR Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNBEKIMAS$0.61$0.56$0.55▼$1.75$3.54M0.373,162 shs30 shsCTTCCalmare Therapeutics$0.00$0.00▼$0.02N/AN/AN/AN/ANVTRQNuvectra$0.02-25.0%$0.02$0.01▼$4.30N/AN/AN/A382,600 shsRGINRegenicin$0.01$0.00$0.00▼$0.01$829KN/A7,333 shsN/ATEARTearLab$0.06-1.9%$0.06$0.02▼$0.22N/AN/AN/A20,200 shsBeginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNBEKIMAS0.00%0.00%0.00%+12.96%-25.15%CTTCCalmare Therapeutics0.00%0.00%0.00%0.00%0.00%NVTRQNuvectra0.00%0.00%0.00%0.00%0.00%RGINRegenicin0.00%0.00%+4,900.00%+4,900.00%+233.33%TEARTearLab0.00%0.00%0.00%0.00%0.00%The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside himMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASNBEKIMASN/AN/AN/AN/AN/AN/AN/AN/ACTTCCalmare TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANVTRQNuvectraN/AN/AN/AN/AN/AN/AN/AN/ARGINRegenicinN/AN/AN/AN/AN/AN/AN/AN/ATEARTearLabN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNBEKIMASN/AN/AN/AN/ACTTCCalmare TherapeuticsN/AN/AN/AN/ANVTRQNuvectraN/AN/AN/AN/ARGINRegenicinN/AN/AN/AN/ATEARTearLabN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNBEKIMASN/AN/AN/AN/A$0.03 per shareN/ACTTCCalmare TherapeuticsN/AN/AN/AN/AN/AN/ANVTRQNuvectraN/AN/AN/AN/AN/AN/ARGINRegenicinN/AN/AN/AN/A($0.04) per shareN/ATEARTearLabN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNBEKIMAS-$290KN/A0.00∞N/AN/A-7,902.31%-5,274.01%N/ACTTCCalmare TherapeuticsN/AN/A0.00N/AN/AN/AN/AN/AN/ANVTRQNuvectraN/AN/A0.00∞N/AN/AN/AN/AN/ARGINRegenicin-$640KN/A0.00∞N/AN/AN/AN/AN/ATEARTearLabN/AN/A0.00∞N/AN/AN/AN/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASNBEKIMASN/AN/AN/AN/AN/ACTTCCalmare TherapeuticsN/AN/AN/AN/AN/ANVTRQNuvectraN/AN/AN/AN/AN/ARGINRegenicinN/AN/AN/AN/AN/ATEARTearLabN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNBEKIMASN/A0.120.12CTTCCalmare TherapeuticsN/AN/AN/ANVTRQNuvectraN/AN/AN/ARGINRegenicinN/AN/AN/ATEARTearLabN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNBEKIMASN/ACTTCCalmare TherapeuticsN/ANVTRQNuvectraN/ARGINRegenicin0.01%TEARTearLabN/AInsider OwnershipCompanyInsider OwnershipASNBEKIMAS7.80%CTTCCalmare Therapeutics17.50%NVTRQNuvectra2.90%RGINRegenicinN/ATEARTearLab5.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableASNBEKIMAS115.80 million5.35 millionNot OptionableCTTCCalmare Therapeutics7N/AN/ANot OptionableNVTRQNuvectra197N/AN/ANot OptionableRGINRegenicin3165.77 millionN/ANot OptionableTEARTearLab34N/AN/ANot OptionableRGIN, ASNB, TEAR, CTTC, and NVTRQ HeadlinesSourceHeadlineHarrow Announces New Appointments to its Board of Directorsfinance.yahoo.com - January 29 at 8:03 AMFor Dry Eye, Transnasal Neurostimulator Activates Real Tearsmedscape.com - November 1 at 12:07 PMSTRATA Skin Science Announces Leadership Changebenzinga.com - October 30 at 8:29 AMVeterinary ophthalmologymedscape.com - September 19 at 1:29 PMOcular Therapeutix™ Announces Appointment of New Board Memberfinance.yahoo.com - July 12 at 9:18 AMDry Eye Diagnosis Systems Market Growth Holds Strong: Topcon, TearLab, NIDEK - openPRnews.google.com - April 28 at 8:43 AMPrevalence of dry eye disease | OPTH - Dove Medical Pressnews.google.com - April 27 at 5:35 AMAnterior eye parameters and lens thickness measured by an ... - Nature.comnews.google.com - April 19 at 12:25 PMDry Eye Treatment Devices Market Growth Trends Analysis and ... - Digital Journalnews.google.com - April 11 at 9:24 AMOptometrist Joins Cincinnati Eye Care Practice - EIN Newsnews.google.com - April 5 at 9:34 AMForm DEF 14A UNITED STATES LIME & - StreetInsider.comnews.google.com - March 31 at 9:51 AMOcular Allergy Diagnostic Systems Market Size 2023 with End-user Industries, Segments Covered in the Reportmarketwatch.com - January 15 at 6:18 PMArtificial Tears: An Optometrist's perspective | OPTO - Dove Medical Pressnews.google.com - January 9 at 2:11 PMLow-level Light in Meibomian Gland Disease | OPTH - Dove Medical Pressnews.google.com - December 6 at 3:39 AMNeurotrophic Keratitis: Diagnosing and Treating a Rare Find! - Healionews.google.com - December 2 at 10:11 AMNeurotrophic Keratitis: Detecting, Tracking, and Treating an Elusive Condition: A Wheel of Knowledge Challenge! - Healionews.google.com - December 2 at 12:09 AMPersonalized Management of Dry Eye Disease: Beyond Artificial Tears | OPTH - Dove Medical Pressnews.google.com - November 23 at 3:07 PMDED: Developing a 360° diagnosis and treatment plan - Optometry Timesnews.google.com - November 22 at 5:00 AMJapan Dry Eye Disease Diagnostics & Treatment Market Analysis and Forecast up to 2030 - Digital Journalnews.google.com - November 21 at 11:56 PMOptician Awards: Building better relationships - Optician Onlinenews.google.com - November 18 at 7:24 PMThailand Dry Eye Disease Diagnostics & Treatment Market Development Trends – The C-Drone Review - The C-Drone Reviewnews.google.com - November 18 at 4:26 AMTearLab rebrands as Trukera Medicalopticianonline.net - September 20 at 7:00 PMTrukera™ Medical Launches New ScoutPro™ Osmolarity Systemfinance.dailyherald.com - September 12 at 3:51 PMHousing Authority officials want more police help at East Acresyahoo.com - September 9 at 10:47 PMMedia Sentiment Over TimeTop HeadlinesBuy the Dip in Paychex, Inc. for a Pay Check at RetirementApril 2, 2024 11:07 AMView Buy the Dip in Paychex, Inc. for a Pay Check at RetirementBuy the Dip in Netflix Stock, It Won’t Last LongApril 19, 2024 8:32 AMView Buy the Dip in Netflix Stock, It Won’t Last LongBargain Hunting: 3 Stocks With RSIs That Scream OversoldApril 19, 2024 8:59 AMView Bargain Hunting: 3 Stocks With RSIs That Scream OversoldWD-40 Company Greases the Wheels of Growth and ProfitsApril 10, 2024 10:12 AMView WD-40 Company Greases the Wheels of Growth and ProfitsWalt Disney’s Proxy Tug of War Pulls Shares to 52-Week Highs April 1, 2024 9:02 AMView Walt Disney’s Proxy Tug of War Pulls Shares to 52-Week Highs All Headlines Company DescriptionsEKIMASOTCMKTS:ASNBEKIMAS Corp. engages in the development of polymer materials, which provide characteristics in the design and development of medical devices. Its biomaterials are used in devices that are designed for treating a range of anatomical sites and disease states. The firm's products include ChronoFlex, ChronoSil, HydroMed, HydroThane, and PolyBlend. The company was founded in 1993 and is headquartered in Las Vegas, NV.Calmare TherapeuticsOTCMKTS:CTTCCalmare Therapeutics Incorporated, a medical device company, develops and commercializes products and technologies for chronic neuropathic pain and wound care affliction patients in the United States. Its flagship medical device is Calmare Pain Therapy Device, a non-invasive and non-addictive modality for the treatment of chronic and neuropathic pain. The company was formerly known as Competitive Technologies, Inc. and changed its name to Calmare Therapeutics Incorporated in August 2014. Calmare Therapeutics Incorporated was founded in 1968 and is based in Fairfield, Connecticut.NuvectraOTCMKTS:NVTRQNuvectra Corporation, a neurostimulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. The company offers Algovita, a spinal cord stimulation system for the treatment of chronic intractable pain of the trunk and limbs. It is also developing Virtis, a sacral neuromodulation (SNM) system for the treatment of chronic urinary retention and overactive bladder; and technologies to support other indications, including SNM for the treatment of overactive bladder and deep brain stimulation to treat Parkinson's disease. The company serves hospitals, surgery centers, and medical facilities through a direct sales force and third-party distributors in the United States and Europe. Nuvectra Corporation was founded in 2008 and is headquartered in Plano, Texas.RegenicinOTCMKTS:RGINRegenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. Its product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. The company products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was incorporated in 2007 and is headquartered in Little Falls, New Jersey.TearLabOTCMKTS:TEARTearLab Corporation operates as an in-vitro diagnostic company in the United States and internationally. It offers TearLab Osmolority System, a proprietary in vitro diagnostic tear testing platform that measures tear film osmolarity for the diagnosis of dry eye disease; and enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. Its TearLab Osmolarity System consists of TearLab disposable, a single-use microfluidic microchip; TearLab pen, a hand-held device that interfaces with the TearLab disposable; and TearLab reader, a small desktop unit that allows for the docking of the TearLab pen, as well as provides a quantitative reading for the operator. The company was formerly known as OccuLogix, Inc. TearLab Corporation was founded in 1996 and is headquartered in San Diego, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.